ClinicalTrials.gg
CompletedNCT03325374BLBUpdated Apr 7, 2020

BLB Study Back or Leg Pain and Bladder Symptoms Study

An observational study in Cauda Equina Syndrome and Functional Neurological Disorder, sponsored by University of Edinburgh. Completed at 1 site in United Kingdom. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2020-04-07.

Sponsored by University of Edinburgh · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
16 Years to 100 Years
Sex
All
01

Study summary

The research focuses on Cauda Equina Syndrome (CES) which describes damage to the nerves in the lower back which supply bladder, bowels, sexual function and the legs usually from slipped discs in the spine.

CES is as common as multiple sclerosis and is diagnosed using an MRI scan of the spine, 'scan positive' CES. However, about 50% of people presenting with the symptoms of CES have MRI scans which do not explain their symptoms, 'scan negative' patients. The BLB study will be the first large clinical study comparing patients with 'scan positive' and 'scan negative' CES. All patients admitted to the Western General Hospital, Edinburgh with possible CES will be invited to participate. The study consists of detailed history taking, examination and a questionnaire following up patient's symptoms at three months.

The study aims to see what differences exist between the 'scan positive' and 'scan negative' groups, help doctors understand more about the outcomes of both groups and discover the number of patients with 'scan negative' CES who have functional disorders (previously called medically unexplained or conversion disorders) or undiagnosed neurological disorders.

Read the detailed description

Uro-neurological disorders are those in which there is a disturbance of bladder function related to a neurological cause. However, many patients with Uro-Neurological disorders are not found to have explanatory abnormalities despite adequate clinical and radiological investigation, so-called 'scan negative' patients. The BLB study will investigate this problem through an acute disorder, Cauda Equina Syndrome (CES), to provide a better understanding of scan-negative Uro-Neurological disorders.

CES is a devastating condition caused by compression of the cauda equina nerve roots resulting in bowel, bladder and sexual dysfunction with potential lower limb weakness. CES requires urgent surgery and has serious potential morbidity and medico-legal consequences1. Suspected acute CES has a minimum incidence of 11 per 100,000 making it twice as common as multiple sclerosis. However, in the two largest studies both retrospective and from Edinburgh, 43-48% of patients with clinical CES were 'scan-negative' and indeed received no other diagnosis 1,2.

Little is known about patients with 'scan negative' CES and nothing is known about their outcome. Our two studies in Edinburgh found basic clinical and demographic characteristics could not distinguish 'scan positive' and 'scan negative' groups 1,2. However, on the basis of clinical experience, and now prospective pilot data, the investigators hypothesise that many of these patients have either an acute functional disorder or, in some cases, sacral nerve damage not seen on imaging but detectable on anal sphincter EMG. Functional disorders, also called psychogenic/non-organic disorders, refer to genuinely experienced physical symptoms which can be positively identified as not related to underlying neurological disease3. Finding out about the diagnosis of patients with 'scan negative' CES would enable them to access treatment and improve their outcome as well as creating better service provision for them in the long term. There is also limited data on long term outcome in patients with 'scan positive' CES and a wish for knowledge from the medical community about what the priorities for patients with 'scan positive' CES are after discharge. The investigators have called the study subsection 'Back or Leg pain with Bladder symptoms' (BLB) study because this most accurately describes the symptoms patients have and we know that describing something negatively to patients (e.g. medically unexplained symptoms)is found by patients to be unhelpful.

The BLB study asks three main questions; do patients with 'scan negative' CES have symptoms of bowel, bladder, sexual dysfunction and lower limb weakness and sensory abnormalities due to a functional disorder?; do a proportion of patients with 'scan negative' CES have missed neurological disease?; what are the outcomes of patients with 'scan negative' and 'scan positive' CES after three months?

02

Conditions studied

  • Cauda Equina Syndrome
  • Functional Neurological Disorder

Browse trials for

03

In context

Conversion Disorder

89 studies on the registry are indexed under Conversion Disorder; 34 are open to participants now.

This study's enrollment of 100 is above the median of 60 across 37 observational studies indexed under Conversion Disorder.

Browse Conversion Disorder studies →

Lead sponsor

University of Edinburgh is the lead sponsor of 403 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

161 participants admitted to the Western General Hospital, Edinburgh with possible CES.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to give
  2. Able to complete online or paper questionnaire.
  3. Patients admitted to the regional neurosurgical unit, Western General Hospital, Edinburgh with suspected cauda equina syndrome for an MRI scan. Demographic data from all patients attending any NHS Lothian site who have an MRI scan for suspected CES.

Exclusion criteria

Exclusion Criteria:

  1. Age less than 16
  2. Inability to communicate (e.g. do not speak English)
  3. Inability to complete written or oral surveys or give
  4. Age over 100. The upper age limit is set at 100 to allow the greatest number of participants the opportunity to take part. As the study is a follow up study concerns about mortality and high drop out in this age group led to the upper limit of 100 being set.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • BLB patients

    Patients admitted for urgent MRI with possible cauda equina syndrome will be consented for questionnaires and examination.

    Other: Questionnaires and examination

Interventions

  • OtherQuestionnaires and examination

    Patients with in the BLB patients study will have interview and questionnaire carried out.

06

What researchers measure

Primary outcomes

  1. What proportion of patients with 'scan negative' CES have a functional disorder by clinical consensus.

    Percent of patients with 'scan negative' CES and a functional disorder.

    Time frame: Nov 15-Aug 18

Secondary outcomes

  1. Demographics (age, gender, work status) in patients with 'scan positive' and 'scan negative' CES.

    Demographics

    Time frame: Nov 15-Aug 18

  2. Neurological examination findings, using Medical Research Council (MRC) grading and standardised sensory and reflex examinations in patients with 'scan positive' and 'scan negative' CES.

    MRC grading of strength (0-5, from no power to full power)

    Time frame: Nov 15-Aug 18

  3. Hospital Anxiety and Depression (HADs) scores and Structured clinical interview for DSM (SCID) findings in patients with 'scan positive' and 'scan negative' CES at onset of symptoms and HADs scores three months after symptom onset.

    Hospital Anxiety and Depression (HADs) scores (\<8 negative, 8-10 mild, 8-14 moderate, 15-21 severe).

    Time frame: Nov 15-Aug 18

  4. Patient priorities after discharge rated using a visual analogue scale. Options will be pain, bladder symptoms, bowel symptoms, sexual function, sensory disturbance, financial, worry/stress/low mood.

    visual analogue scale from 1 would most value help with to 8 would least value help required

    Time frame: Nov 15-Aug 18

  5. The number of patients with 'scan negative' CES have other neurological disease causing their symptoms.

    Number of patients who have a neurological diagnosis explaining their symptoms at up to one year after discharged with CES symptoms.

    Time frame: Nov 15-Aug 18

  6. The number of patients with 'scan negative' CES who have sacral nerve dysfunction found on EMG.

    with 'scan negative' CES who have sacral nerve dysfunction found on EMG.

    Time frame: Nov 15-Aug 18

  7. Bladder function using Urinary Symptom Profile (USP) in patients with 'scan positive' and 'scan negative' CES at symptom onset and at three months after discharge.

    Urinary Symptom Profile splits symptoms up into stress incontinence(0 none to 9 severe), overactive bladder (0 none to 21 severe), low stream (0 none to nine severe)

    Time frame: Nov 15-Aug 18

  8. Bowel function using The Neurogenic Bowel Dysfunction score in patients with 'scan positive' and 'scan negative' CES at symptom onset and at three months after discharge.

    10-13 is moderate dysfunction, 14 or over is severe dysfunction

    Time frame: Nov 15-Aug 18

  9. Sexual function using the Arizona Sexual Experiences Questionnaire in patients with 'scan positive' and 'scan negative' CES at symptom onset and at three months after discharge.

    Abnormal is \>19 or 5 or more on any item or 4 or more on three items

    Time frame: Nov 15-Aug 18

07

Study locations

1 site
  • Department of Neurosciences, Western General Hospital
    Edinburgh, EH4 2XU, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03325374
Collaborators
NHS Lothian
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
Nov 2015
Primary completion
May 2018
Completion
Jan 2020
Last update
Apr 7, 2020

Study contacts

Ingrid Hoeritzauer
principal investigator · University of Edinburgh

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion